 |
 Gerald L. Andriole Urologist combats prostatic diseases |
 |
|
|
|
|
 |
||||||
|
|
|||||||||||||||||||||||||||
|
 |
|
Type 2 diabetics needed for heart disease research Volunteers with type 2 diabetes are needed for a study in the School of Medicine. The study, called BARI 2D (bypass angioplasty revascularization investigation of type 2 diabetes), is part of an international effort to prevent and control the progression of coronary disease, a dangerous clogging of the heart's blood vessels that recently has been identified as a significant problem for people with diabetes. "A lot of people with diabetes have coronary disease and don't even know it," said Ronald J. Krone, M.D., professor of medicine. "In addition, diabetes has become an extremely complex disease to manage because so many new tools, drugs and techniques are being developed. By combining the School of Medicine's expertise in cardiology and diabetes, we're offering patients the opportunity to continue under the care of their own physician while at the same time receiving the most advanced treatments available through this study." Krone and his colleagues, Richard G. Bach, M.D., associate professor of medicine; Mark S. Weinfeld, M.D., assistant professor of medicine; and Janet B. McGill, M.D., associate professor of medicine, will lead the University's team in this North American trial. An earlier study completed by this research consortium found that people with both diabetes and coronary disease are more likely to die than people with coronary disease alone. The team now is exploring whether the latest medications can prevent individuals with diabetes from requiring heart surgery or angioplasty, re-opening a clogged artery with a balloon. They also will explore the potential benefits of bypass surgery or angioplasty in treating coronary disease early in this population. Interested individuals with type 2 diabetes who have never had bypass surgery and who have not had angioplasty in the past year will be screened for coronary disease with a stress test to determine whether they are eligible for the trial. Participants then will be randomly assigned to receive either a drug regimen combining the latest medical therapies or a combination of medications and the appropriate surgical procedure. In addition, they will be assigned to receive different regimens of diabetic medications. Participants must return for monthly follow-up evaluations for six months and will be called for questioning annually for five years. Many of the medications used in the trial are free of charge. All tests and surgical procedures must be covered by insurance; most insurance companies, including Medicare, will cover these costs. For more information or to volunteer for this study, contact Sandra Aubuchon at 747-5587. |
|
||||||||||||||||||||||||
|
|